IMAT S.A.S (Site 2202)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Triple-negative breast cancer

Running trials

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Toll Free Number